Stephen Ubl, PhRMA president and CEO (Adrien Villez for Endpoints News)
PhRMA, Eli Lilly, other drug companies push back on FDA's draft guidance about communicating off-label use
Big Pharma is pushing back on draft guidance published by the FDA this fall that aims to clarify how …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
